Skip to content

Pentoxifylline, as nonselective phosphodiesterase inhibitor, attenuate paraquat-induced hepatic damage: in vivo and molecular docking insights

Jul 2026 · Drug and chemical toxicology (New York, N.Y. 1978) · Vol 49, pp. 825 - 834 · 0 citations · 51 references
Medicine

TL;DR

PTX administration may prevent PQ-induced hepatic damage in mice, potentially by inhibiting free radical formation and molecular docking analysis suggests that PTX may reduce PQ-induced oxidative stress by competitively inhibiting the FAD-binding site of xanthine oxidase, and by engaging a non-active-site region of NADPH oxidase.

Abstract

Abstract Oxidative stress has a key role in paraquat (PQ)-mediated hepatic failure. Considering the known antioxidant and anti-inflammatory properties of nonselective phosphodiesterase inhibitors, this study investigated the potential of pentoxifylline (PTX) to counteract acute PQ-induced liver damage. The molecular interactions of PQ and PTX with key oxidative stress enzymes (NADPH oxidase, xanthine oxidase) were investigated by molecular docking using AutoDock 4.2.6. For in vivo studies, thirty-six mice were randomized into six groups: a normal saline control, a PQ-intoxicated group (20 mg/kg, single dose), a PTX control group (100 mg/kg for 3 days), and three treatment groups that received PTX (25, 50, or 100 mg/kg) for three consecutive days, starting one hour after PQ administration. Blood and liver tissues were collected 24 hours after the final dose for biochemical and histological analysis. The PQ administration resulted in a significant increase in serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), hepatic lipid peroxidation (LPO), and nitric oxide (NO) levels, while concurrently decreasing antioxidant capacity (TAC), total thiol molecule (TTM), and superoxide dismutase (SOD) activity in liver tissue. PTX treatment effectively improved serum hepatic enzymes, LPO, TTM, and SOD levels, as corroborated by histological findings. Moreover, molecular docking analysis suggests that PTX may reduce PQ-induced oxidative stress by competitively inhibiting the FAD-binding site of xanthine oxidase, and by engaging a non-active-site region of NADPH oxidase. This study indicates PTX administration may prevent PQ-induced hepatic damage in mice, potentially by inhibiting free radical formation. Further research is needed to validate the proposed enzymes inhibition mechanisms and assess PTX’s potential in acute PQ poisoning.

View source

Similar papers

Open access Aug 2026

Chrysin attenuates pentadecafluorooctanoic acid-induced hepatotoxicity in male Wistar rats via modulation of oxidative stress, inflammation, and metabolic dysfunction

Overall, chrysin demonstrates potent protective potential against PFOA-induced liver injury and may serve as a promising therapeutic candidate for environmental toxin-associated hepatotoxicity.

A. B. Awolesi, Moses C. Antiya, S. A. Praise · 0 citations
Jul 2026

Histidine, carnosine, and ergothioneine attenuate pyrazole/LPS-induced hepatotoxicity through modulation of CYP2E1, Nrf2, and NF-κB signaling in mice

Histidine, carnosine, and ergothioneine protected against Pyr + LPS-induced hepatic injury and reduced oxidative stress and were accompanied by alterations in CYP2E1 protein levels and NF-κB/Nrf2/HO-1-related gene expression; however, further studies are needed to clarify the underlying mechanisms.

İlknur Genç, F. H. Karpuzoğlu, İlayda Sözmen et al. · 0 citations
Open access Jul 2026

Evaluation of the nephroprotective potential of chrysin against pentadecafluorooctanoic acid-induced kidney dysfunction in male Wistar rats

It is suggested that chrysin confers significant nephroprotective effects against PFOA-induced renal injury by mitigating oxidative stress, inflammation, and ion transport disruption, supporting its therapeutic potential as a promising nephroprotective agent for protecting against environmentally induced kidney injury.

A. B. Awolesi, Tomisin M. Koledoye, Rereloluwa M. Adesina et al. · 0 citations
Aug 2026

Protective effect of Dapagliflozin on hepatic encephalopathy induced by thioacetamide in rats: involvement of ERK, JNK, and Nrf2/HO-1 pathways.

Hepatic encephalopathy (HE) is a neuropsychiatric disorder associated with oxidative stress, neuroinflammation, and hyperammonaemia secondary to hepatic dysfunction. This study aimed to investigate dapagliflozin's effects (DAPA) against HE induced by thioacetamide (TAA) in rats and to elucidate the roles of the extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK) and nuclear factor erythroid 2-related factor 2/Heme oxygenase-1 (Nrf2/HO-1) signaling pathways. HE was induced by injection of TAA (200 mg/kg) intraperitoneally 2 times every other day. Two groups were pretreated with DAPA at 5 and 10 mg/kg for 15 days; on the 13th day, rats were given TAA (200 mg/kg, i.p.) twice, 2 days apart. Behavioral assessments, including object recognition and rotarod tests, were conducted, and serum and tissue samples were collected for biochemical and molecular analyses. DAPA pretreatment ameliorated TAA effects, improved recognition memory, enhanced muscular tone and motor coordination. DAPA also reduced ALT (alanine aminotransferase), AST (aspartate aminotransferase), and ammonia serum levels. Additionally, it restored antioxidant balance, decreased malonaldehyde (MDA) and increased reduced glutathione (GSH). Moreover, it reduced tissue inflammation and inhibited apoptosis; where tumor necrosis factor-alpha (TNF-α) and caspase-3 expression were suppressed. DAPA was associated with increased Nrf2/HO-1 pathway-related protein expression while decreasing pERK/total ERK and pJNK/total JNK ratios, along with nuclear factor kappa-light-chain-enhancer of activated B cells, p65 subunit (NF-κB-p65) protein expression. Histopathologically, DAPA improved hepatic and brain architecture. Collectively, DAPA exhibits hepatoprotective and neuroprotective effects against TAA-induced HE accompanied by modulation in oxidative-, inflammatory-, and apoptotic-related protein expression, highlighting its therapeutic potential in hepatic encephalopathy.

Hadir Farouk, Salma A. El-Marasy, M. S. Khattab et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.